Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT ID: NCT00189904

Last Updated: 2012-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-07-31

Brief Summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.

Conditions

HIV Infections

Keywords

HIV

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

IMVAMUNE (MVA-BN)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male subjects between 18 and 49 years of age or female subjects between 18 and 55 years of age who provided informed consent.
• Women with negative pregnancy test.
• Women of childbearing potential must use an acceptable method of contraception.
• Cardiac enzymes within ULN.
• White blood cells ≥ 2500/mm3 and < 11,000/ mm3.
• Absolute neutrophil count ≥ 1000/mm3.
• Adequate renal function.
• Adequate hepatic function.
• Negative hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).
• Negative antibody test to hepatitis C virus (HCV).
• Negative urine glucose by dipstick or urinalysis.
• Normal 12-lead electrocardiogram.
• Availability for follow-up during the study.

Groups 1 and 3 (All vaccinia-naïve subjects) additionally:

• No history of known or suspected previous smallpox vaccination.
• No detectable vaccinia scar.
• No military service prior to 1989 or after January 2003.

Groups 2 and 4 (All previously vaccinated subjects) additionally:

• History of at least one previous smallpox vaccination
• Time since most current smallpox vaccination > 10 years.

Groups 1 and 2 (All HIV Infected subjects) additionally:

• Documented HIV-1 infection
• Plasma HIV-1 RNA level < 400 copies/mL at screening.
• CD4 cells ≥ 350/µL
• Haemoglobin ≥ 9.0 g/dL.
• Platelets ≥ 100,000/mm3.
• AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 3 x ULN

Groups 3 and 4 (All Healthy subjects) additionally:

• Negative ELISA for HIV.
• Haemoglobin >11 g/dL.
• Platelets ≥ 140,000/mm3.
• AST (SGOT), ALT (SGPT) and alkaline phosphatase without clinically significant findings

Exclusion Criteria

• Pregnant or breast-feeding women.
• Uncontrolled serious infection i.e. not responding to antimicrobial therapy.
• History of any serious medical condition (other than HIV infection).
• History of or active autoimmune disease.
• Known or suspected impairment of immunologic function (other than HIV infection).
• History of malignancy.
• History or clinical manifestation of clinically significant and severe haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
• Clinically significant mental disorder not adequately controlled by medical treatment.
• Any condition which might interfere with study objectives.
• History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, or any other heart condition under the care of a doctor.
• History of an immediate family member with onset of ischemic heart disease before age 50.
• Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool.
• History of chronic alcohol abuse and/or intravenous drug abuse.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Known previous allergic reaction to immunoglobulins.
• Known allergies to cidofovir or probenecid.
• History of anaphylaxis or severe allergic reaction.
• Acute disease (illness with or without a fever) at the time of enrollment.
• Temperature >100.4°F at the time of enrollment.
• Subjects undergoing treatment for tuberculosis infection or disease.
• Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior or after study vaccination.
• Having received any vaccinations or planned vaccinations with a killed vaccine within 14 days prior or after study vaccination.
• Chronic administration of immuno-suppressant or immune-modifying drugs.
• Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
• Administration or planned administration of immunoglobulins and/or any blood products.
• Use of any investigational or non-registered drug or vaccine.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Bavarian Nordic

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard N Greenberg, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky School of Medicine

Locations

Indiana University School of Medicine

Indianapolis, Indiana, United States

University of Kentucky Medical Center

Lexington, Kentucky, United States

Washington University School of Medicine

St Louis, Missouri, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Vanderbilt AIDS Clinical Trials Center

Nashville, Tennessee, United States

Countries

United States

References

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Badeker N, Vollmar J, Chaplin P. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.

Reference Type: DERIVED

PMID: 23225902 (View on PubMed)

Other Identifiers

HHSN266200400072C

Identifier Type: -

Identifier Source: secondary_id

POX-MVA-010

Identifier Type: -

Identifier Source: org_study_id